معرفی
Rozalyn Levine Rodwin, MD, is an Assistant Professor in Pediatrics at Yale School of Medicine and Director of the Pediatric HEROS Survivorship Program. Her roles include leading survivorship care programs and conducting research on minimizing treatment-related toxicities in childhood cancer survivors. She completed her medical degree at New York Medical College, residency at Yale-New Haven Hospital, and a pediatric hematology/oncology fellowship at Yale School of Medicine. Her research focuses on late effects of cancer treatments, particularly chemotherapy-induced peripheral neuropathy and neurocognitive outcomes.
Education:
- MD – New York Medical College (2014)
- Residency in Pediatrics – Yale-New Haven Hospital (2017)
- Fellowship in Pediatric Hematology/Oncology – Yale School of Medicine (2020)
Research Interests: Dr. Rodwin’s work addresses long-term health outcomes in pediatric cancer survivors, including motor/sensory impairments, neurocognitive function, and biomarker discovery for treatment toxicities. Her clinical programs emphasize early detection and management of late effects through multidisciplinary approaches.
Key Contributions:
- Developed the HEROS Childhood Cancer Survivorship Clinic (since 2021)
- Published studies on chemotherapy-induced neuropathy, longitudinal survivorship outcomes, and clinical decision-making
- Recipient of the 2020 American Society of Clinical Oncology Conquer Cancer Merit Award
Grants & Trials: Leading or participating in clinical trials evaluating novel therapies (e.g., gene-edited CD34+ cells for sickle cell disease) and survivorship interventions. Active in translational research collaborations with institutions like St. Jude Children’s Research Hospital.
Labs/Teams: Collaborates with the Cancer Prevention and Control T32 Program and Janeway Society. Engaged in interdisciplinary teams addressing survivorship care and pediatric oncology innovation.
